Semaglutide Reduces Cardiovascular Events by 20% in High-Risk Patients | SELECT Trial

A new analysis of the SELECT trial has revealed that semaglutide, a medication initially developed for type 2 diabetes, significantly reduces the risk of major adverse cardiovascular events (MACE) by 20% compared to placebo, particularly in patients exhibiting signs of potential liver fibrosis. The findings, published on April 2, 2026, in Nature Medicine, suggest a broader range of benefits for semaglutide beyond weight loss.

The prespecified analysis focused on data from the SELECT trial, a randomized controlled study investigating the effects of once-weekly subcutaneous semaglutide 2.4 mg in individuals with obesity and established cardiovascular disease. Researchers examined the relationship between semaglutide’s impact on cardiovascular outcomes and baseline levels of fibrosis, as indicated by the Fibrosis-4 (F4) index – a non-invasive marker of liver fibrosis.

Semaglutide and Cardiovascular Risk Reduction

The SELECT trial, as highlighted in recent reports from The Lancet and The New England Journal of Medicine, initially demonstrated semaglutide’s ability to reduce the risk of adverse cardiovascular events in obese patients. This new analysis delves deeper, identifying a subgroup that appears to benefit even more significantly: those with indications of liver fibrosis.

The Fibrosis-4 index assesses the risk of advanced liver disease based on readily available blood tests – age, platelet count, AST, and ALT levels. A higher F4 index suggests a greater likelihood of fibrosis. The analysis revealed that semaglutide’s protective effect against MACE was more pronounced in patients with elevated F4 indices at the start of the trial.

The Link Between Liver Fibrosis and Heart Health

The connection between liver fibrosis and cardiovascular disease is increasingly recognized by medical researchers. Non-alcoholic fatty liver disease (NAFLD), often associated with obesity, can progress to non-alcoholic steatohepatitis (NASH), which involves inflammation and fibrosis of the liver. NASH is a growing public health concern and is linked to an increased risk of heart disease, stroke, and other cardiovascular complications.

According to reporting from Google News, the findings suggest that semaglutide may offer a dual benefit by addressing both obesity and underlying liver fibrosis, thereby reducing cardiovascular risk. This is particularly relevant given the rising prevalence of both conditions.

Implications for Patient Care

The results of this analysis could influence clinical guidelines for the use of semaglutide. While the drug is already approved for weight management and type 2 diabetes, the added benefit of cardiovascular protection, especially in patients at risk of liver fibrosis, may broaden its application. However, further research is needed to fully understand the mechanisms underlying this effect and to determine the optimal patient population for semaglutide therapy.

As reported by Docwire News, the SELECT trial analysis demonstrates that semaglutide’s heart benefits extend beyond weight loss, offering a potential new avenue for cardiovascular disease prevention and treatment.

The October 22, 2025, publication in The Lancet, as summarized in another report, confirmed that semaglutide reduced major adverse cardiovascular events in patients with overweight or obesity. This latest analysis builds upon those findings by identifying a specific subgroup that may experience even greater benefits.

Researchers emphasize the need for continued investigation into the interplay between liver health, obesity, and cardiovascular disease. Understanding these complex relationships is crucial for developing effective strategies to prevent and treat these increasingly prevalent conditions.